MedTrace Logo

Booster Study of SpikoGen COVID-19 Vaccine

NCT05542862 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-09-17

No results posted yet for this study

Summary

The purpose of the study is to assess the effectiveness of Spikogen vaccine when used as a 3rd or 4th dose booster in adults who have been previously vaccinated with any Covid-19 vaccine types, including mRNA vaccine, adenoviral vector vaccines, recombinant protein vaccines, or inactivated virus vaccines.

Conditions

Interventions

BIOLOGICAL

SpikoGen vaccine

Recombinant spike protein based Covid-19 vaccine

Sponsors & Collaborators

  • Australian Respiratory and Sleep Medicine Institute Ltd

    collaborator UNKNOWN

  • Cinnagen

    collaborator INDUSTRY

  • Vaxine Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Dimitar Sajkov, MD/PhD · ARASMI

  • Nikolai Petrovsky, MD/PhD · Vaxine Pty Ltd

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-07
Primary Completion
2023-12-31
Completion
2025-09-16

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05542862 on ClinicalTrials.gov